Raleigh, United States
Gemelli Biotech, founded in 2018, is a United States-based startup specializing in the Biotechnology, Health Care, and Pharmaceutical industries. Their slogan, "We develop and distribute precision diagnostics for GI diseases," encapsulates their commitment to leveraging breakthroughs in microbiome science. They offer non-invasive precision diagnostics that empower clinicians to identify validated biomarkers and optimize treatment for gastrointestinal conditions such as SIBO, IMO, excessive hydrogen sulfide, and post-infectious IBS.
In terms of financial traction, Gemelli Biotech secured a $19.00M Series A investment on 01 June 2022, with backing from notable investors like CerraCap Ventures, The Cedars-Sinai Accelerator, Carolina Angel Network, and Blue Ox Healthcare Partners. This capital injection underscores investor confidence in their cutting-edge diagnostics solutions and potential scalable impact on the healthcare sector.
